中文名称 | 英文名称 | CAS号 | 化学式 | 分子量 |
---|---|---|---|---|
1,2,3,4-四-O-乙酰基-β-D-葡萄吡喃糖 | 1,2,3,4-tetra-O-acetyl-β-D-glucopyranose | 13100-46-4 | C14H20O10 | 348.307 |
1,6-脱水-β-D-葡萄糖-2,3,4-三邻醋酸 | 2,3,4-tri-O-acetyllevoglucosan | 13242-55-2 | C12H16O8 | 288.254 |
—— | 2,3,4,5-tetra-O-acetyl-D-glucopyranose | —— | C14H20O10 | 348.307 |
麦芽糖 | Maltose | 16984-36-4 | C12H22O11 | 342.3 |
—— | Lactose | 63-42-3 | C12H22O11 | 342.3 |
苯甲基 BETA-D-吡喃葡萄糖苷 2,3,4,6-四乙酸酯 | benzyl-2,3,4,6-tetra-O-acetyl-β-D-glucopyranoside | 10343-13-2 | C21H26O10 | 438.431 |
—— | D-isomaltose | 24822-33-1 | C12H22O11 | 342.3 |
alpha-甲基葡萄糖甙 | methyl-alpha-D-glucopyranoside | 97-30-3 | C7H14O6 | 194.185 |
1,6-脱水-β-D-葡萄糖 | levoglucosan | 498-07-7 | C6H10O5 | 162.142 |
蔗糖 | Sucrose | 57-50-1 | C12H22O11 | 342.3 |
中文名称 | 英文名称 | CAS号 | 化学式 | 分子量 |
---|---|---|---|---|
—— | 1,2,3,4-tetra-O-acetyl-D-glucose | 65620-65-7 | C14H20O10 | 348.307 |
1,2,3,4-四-O-乙酰基-β-D-葡萄吡喃糖 | 1,2,3,4-tetra-O-acetyl-β-D-glucopyranose | 13100-46-4 | C14H20O10 | 348.307 |
—— | 1,2,3,4,2',3',4',6'-octa-O-acetylgentiobiose | 4613-78-9 | C28H38O19 | 678.598 |
1,2,3,6-四-o-乙酰基-alpha-d-吡喃葡萄糖 | 1,2,3,6-tetra-O-acetyl-α-D-glucopyranose | 55286-97-0 | C14H20O10 | 348.307 |
—— | hexan-1-ol 2,3,4,6-tetra-O-acetyl-β-D-glucopyranoside | 76870-85-4 | C20H32O10 | 432.468 |
—— | 2-(2',3',4',6'-Tetra-O-acetyl-β-D-glucopyranosyl)ethanal | 131474-49-2 | C16H22O11 | 390.344 |
—— | methyl 2,3,4,6-tetra-O-acetyl-β-D-glucopyranoside | 4860-85-9 | C15H22O10 | 362.334 |
2,3,4,6-四-o-乙酰基-alpha-d-吡喃葡萄糖苷甲酯 | Acetic acid (2R,3R,4S,5R,6S)-3,5-diacetoxy-2-acetoxymethyl-6-methoxy-tetrahydro-pyran-4-yl ester | 604-70-6 | C15H22O10 | 362.334 |
—— | tetradecyl 2,3,4,6 tetra-O-acetyl-β-D-glucopyranoside | 103279-23-8 | C28H48O10 | 544.683 |
1,3,4,6-O-四乙酰基-2-脱氧-D-吡喃葡萄糖 | 1,3,4,6-tetra-O-acetyl-2-deoxy-D-glucopyranose | 69515-91-9 | C14H20O9 | 332.307 |
The development of selective anticancer vaccines that provide enhanced protection against tumor recurrence and metastasis has been the subject of intense research in the scientific community. The tumor-associated glycoprotein MUC1 represents a well-established target for cancer immunotherapy and has been used for the construction of various synthetic vaccine candidates. However, many of these vaccine prototypes suffer from an inherent low immunogenicity and are susceptible to rapid in vivo degradation. To overcome these drawbacks, novel fluorinated MUC1 glycopeptide-BSA/TTox conjugate vaccines have been prepared. Immunization of mice with the 4’F-TF-MUC1-TTox conjugate resulted in strong immune responses overriding the natural tolerance against MUC1 and producing selective IgG antibodies that are cross-reactive with native MUC1 epitopes on MCF-7 human cancer cells.